TCN2 Pro259Arg (C776G)

TCN2 Pro259Arg — Your B12 Delivery System

Vitamin B12 travels through your bloodstream bound to two different
proteins. About 75-80% binds to haptocorrin | A B12-binding protein
that carries most circulating B12 but cannot deliver it to cells; it is
metabolically inert, which is metabolically inert. The remaining 20-25%
binds to transcobalamin II | The only B12 transport protein that can
deliver the vitamin into cells via the transcobalamin receptor (CD320)
on cell surfaces (encoded by the TCN2 gene), forming
holotranscobalamin | Also called "active B12" or holoTC, this is the
fraction of circulating B12 that is actually available for cellular
uptake (holoTC) --
the only form of B12 that can actually enter your cells. This makes
holoTC a far better marker of functional B12 status than total serum B12.

The TCN2 Pro259Arg variant (rs1801198, c.776C>G) changes a proline to an
arginine at position 259 of the transcobalamin protein. This single amino
acid swap alters the protein's ability to bind and deliver B12, resulting
in measurably lower holoTC levels in carriers of the G allele -- even when
total serum B12 appears normal.

The Mechanism

Transcobalamin II is a 43 kDa protein that binds one molecule of
cobalamin (B12) and delivers it to cells via the
CD320 receptor | Also called the transcobalamin receptor (TCblR),
expressed on virtually all cell surfaces. The
crystal structure | Wuerges et al. solved the structure of human
transcobalamin bound to cobalamin, revealing a two-domain architecture
with B12 buried at the domain interface
of human transcobalamin reveals a two-domain architecture with cobalamin
buried at the interface between an N-terminal barrel and a smaller
C-terminal domain. Position 259 lies in a region that influences the
protein's secondary structure and its affinity for B12. The arginine
substitution (G allele) disrupts this region, reducing the proportion
of transcobalamin that successfully binds B12.

The consequence is straightforward: less B12 gets loaded onto
transcobalamin, so less holoTC circulates, and less B12 reaches your
cells. Total serum B12 may look perfectly normal because the
haptocorrin-bound fraction (which is metabolically useless) is unaffected.
This is why standard B12 blood tests can be misleading for carriers of
this variant.

The Evidence

The landmark study by Miller et al. | Miller JW et al. Transcobalamin II
775G>C polymorphism and indices of vitamin B12 status in healthy older
adults. Blood, 2002 examined
128 healthy older adults and found that Arg/Arg homozygotes (GG) had
significantly lower holoTC (p = 0.006) and higher
methylmalonic acid | MMA is a metabolic byproduct that accumulates when
cellular B12 is insufficient; elevated MMA is a sensitive functional
marker of B12 deficiency (MMA) concentrations (p = 0.02) compared
to Pro/Pro homozygotes, despite similar total B12 levels.

A comprehensive meta-analysis of 34 studies | Oussalah A et al.
Association of TCN2 rs1801198 c.776G>C polymorphism with markers of
one-carbon metabolism and related diseases. Am J Clin Nutr,
2017 confirmed that GG
carriers have significantly lower holoTC (SMD -0.445, 95% CI -0.673
to -0.217, p < 0.001) and higher homocysteine in European-descent
populations (SMD 0.070, 95% CI 0.020-0.120, p = 0.01). The
meta-analysis found no significant association with congenital
abnormalities, cancer, or Alzheimer disease.

Stanislawska-Sachadyn et al. | Stanislawska-Sachadyn A et al. The
transcobalamin 776C>G polymorphism affects homocysteine concentrations
among subjects with low vitamin B12 status. Eur J Clin Nutr,
2010 studied 613 men and
found that the homocysteine-raising effect of the GG genotype is most
pronounced when B12 status is already low, creating a gene-nutrient
interaction where inadequate B12 intake amplifies the genetic effect.

A particularly striking finding came from a study of elderly adults |
Ratan SK et al. Transcobalamin 776C>G polymorphism is associated with
peripheral neuropathy in elderly individuals with high folate intake.
Am J Clin Nutr, 2016: GG
carriers had roughly 3-fold higher odds of peripheral neuropathy, and
when combined with high folate intake (>800 mcg/day), the risk jumped
to OR 6.9. This suggests that excess folic acid may mask B12 deficiency
symptoms while neurological damage progresses -- a concern particularly
relevant for GG carriers.

Practical Implications

The key takeaway is that standard total serum B12 tests may not reflect
your actual cellular B12 status if you carry the G allele. Request
holotranscobalamin (holoTC) or methylmalonic acid (MMA) testing instead,
as these directly measure the B12 that reaches your cells.

For GG carriers, choosing bioavailable forms of B12 (methylcobalamin or
hydroxocobalamin rather than cyanocobalamin) may improve cellular
delivery. Adequate B12 intake is especially important because the
homocysteine-raising effect becomes significant when B12 status drops.

Be cautious with high-dose folic acid supplementation if you carry this
variant. Excess folate can correct the anemia of B12 deficiency while
allowing neurological damage to progress silently. If you also carry
MTHFR variants, use methylfolate rather than folic acid, and ensure B12
status is adequate first.

Interactions

TCN2 Pro259Arg sits at the intersection of the one-carbon metabolism
pathway, where B12 and folate work together. Methionine synthase (MTR,
rs1805087) uses B12 as a cofactor to convert homocysteine to methionine,
while methionine synthase reductase (MTRR, rs1801394) regenerates the
active form of the enzyme. If TCN2 reduces B12 delivery to cells, these
downstream enzymes have less cofactor to work with.

The combination of TCN2 GG with MTHFR C677T variants (rs1801133) is of
particular interest: MTHFR variants impair folate metabolism while TCN2
variants impair B12 delivery, creating a double hit on the methylation
cycle. Both homocysteine recycling and DNA methylation could be
compromised. Individuals carrying risk variants in both genes may benefit
most from combined methylfolate plus methylcobalamin supplementation and
regular homocysteine monitoring.

MTRR A66G (rs1801394) variants may compound the effect of TCN2 by
further reducing the efficiency of B12-dependent methionine synthase
regeneration, potentially amplifying homocysteine elevation in carriers
of both variants.